Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American Academy of Neurology

PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the...
August 10, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE REGULATORY UPDATE ON OMAVELOXOLONE YEAR 2 DATA FROM CARDINAL TRIAL EXPECTED IN FOURTH QUARTER 2020 ENROLLMENT RESUMED IN...
August 03, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020

PLANO, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will...
July 30, 2020 16:05 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors

PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the...
July 28, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19

PLANO, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
July 07, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Promotion and New Hires For Key Leadership Roles

PLANO, Texas, July 07, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the...
June 24, 2020 10:10 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Closes $350 Million Strategic Investment From Blackstone Life Sciences

PLANO, Texas, June 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the receipt of $350...
June 11, 2020 07:30 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment

FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE ...
May 11, 2020 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs

PLANO, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial...
May 04, 2020 16:35 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020

PLANO, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...